AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05582707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15mg
Description: Study participants will be administered pioglitazone (15 mg tablet) either p.o. or enteral (via nasogastric tube). The first dose may be administered prior to surgery or within 3 hours of the end of surgery but must be administered within 24 hours of the index event or time last known normal (TLKN). Pioglitazone (15 mg tablet) administration will continue 3 times daily for 3 weeks, including after hospital discharge, if applicable.
Study NCT04822896 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Exercise
Description: The videos will be prepared by the researchers and will be watched by the physical exercise group, which includes exercises such as shifting the jaw to the side, pushing the tongue forward, jaw opening, sliding the jaw with the tongue, opening the chin with the tongue, opening the chin by pressing the tongue against the palate and shifting the chin with the person's own resistance. Then they will be asked to do the exercises physically. Each exercise will be applied as 2 sets x 10 repetitions. There will be a 30-second break between sets.
Study NCT04822896 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kinesthetic Motor Imagery Exercises
Description: Seven exercises designated as jaw shifting, tongue pushing forward, jaw opening, jaw shifting with tongue, jaw opening with tongue, jaw shifting by pressing the tongue on the palate, and chin shifting with one's own resistance, the videos prepared by the researchers and containing these exercises Once viewed, it will be applied as kinesthetic imagery. Each exercise will be applied as 2 sets x 10 repetitions. There will be a 30-second break between sets.
Study NCT04822896 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Motor Imagery Exercises
Description: Seven exercises designated as jaw shifting, tongue pushing forward, jaw opening, jaw shifting with tongue, jaw opening with tongue, jaw shifting by pressing the tongue on the palate, and chin shifting with one's own resistance, the videos prepared by the researchers and containing these exercises Once viewed, it will be applied as visual imagery. Each exercise will be applied as 2 sets x 10 repetitions. There will be a 30-second break between sets.
Study NCT06080178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine (static group)
Description: When during surgery SBP is below 100mmHg, if the 5ml/kg/h crystalloid limit is already reached, start or increase norepinephrine infusion until SBP is above 100mmHg (with a maximum dose of 0.2mcg/kg/min).
Study NCT06080178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasma-lyte (dynamic group)
Description: Plasmalyte will be administered intravenously:~(1) as a maintenance infusion 1 ml/kg/h (from anaesthesia induction until ICU/PACU discharge); (2) as a fluid bolus until PPV is below or equal to 12% or SBP is above 100mmHg.
Study NCT06080178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine (dynamic group)
Description: When during surgery SBP is below 100mmHg and PPV is below or equal to 12%: start or increase norepinephrine infusion until SBP is above 100mmHg (with a maximum dose of 0.2mcg/kg/min).~When SBP is above 120mmHg: decrease the norepinephrine infusion rate until SBP is below 120mmHg.
Study NCT06283758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: focused power ultrasound mediate inferior perirenal adipose tissue modification
Description: This novel focused power ultrasound is an externally delivered, completely noninvasive focused therapeutic ultrasound device. It is capable of focusing the resulting ultrasound beam to a small cigar-shaped volume and monitoring the temperature of the target area, which leads to the rapid elevation of the peri-renal adipose tissue temperature and the destruction of target tissue eventually.
Study NCT06283758 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: focused power ultrasound mediate inferior perirenal adipose tissue modification
Description: This novel focused power ultrasound is an externally delivered, completely noninvasive focused therapeutic ultrasound device. It is capable of focusing the resulting ultrasound beam to a small cigar-shaped volume and monitoring the temperature of the target area, which leads to the rapid elevation of the peri-renal adipose tissue temperature and the destruction of target tissue eventually.
Study NCT06283758 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-control group
Description: Participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.
Study NCT06392386 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efgartigimod PH20 SC
Description: Subcutaneous injections
Study NCT06384898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Tai Chi
Description: Tai Chi mind-body exercise is a complex, multi-component nonpharmacological intervention integrating physical, psychological, emotional, and behavioral elements.
Study NCT06768450 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online mindfulness meditation
Description: The mindfulness meditation program is adapted from the Breathwork Mindfulness for Stress program. However, it uses shorter meditations designed for individuals who cannot sit for 40 minutes. The mindfulness meditation program encourages greater self-acceptance, kindness, and compassion toward oneself. It builds on this concept by helping participants find pleasure in life despite suffering, fostering kindness and compassion toward others, and increasing social connections to counteract the social isolation common among individuals with chronic and long-term illnesses.~The program will be led by a well-trained Breathwork mindfulness instructor and conducted remotely via Microsoft Teams once a week for 8 weeks. Each session will last 2 to 2.5 hours and consist of body scans, mindful movements, and various meditations, introducing new ideas every week.
Study NCT05517980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP104
Description: Participants will receive loading and/or weekly maintenance subcutaneous (SC) doses of KP104.
Study NCT06778408 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hybrid Palliative Radiation Therapy
Description: Hybrid Palliative Radiation Therapy will be administered to all patients.
Study NCT06779214 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic_L
Description: subject will receive a low-dosage (1\*10\^5) of Bifidobacterium. animalis subsp.Lactis A6 Strain
Study NCT06779214 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: resveratrol_L
Description: subject will receive a low-dosage (300mg/d) of resveratrol
Study NCT06779214 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic_M
Description: subject will receive a medium-dosage (1\*10\^8) of Bifidobacterium. animalis subsp.Lactis A6 Strain
Study NCT06779214 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic_H
Description: subjects will receive a high-dosage (1\*10\^10) of Bifidobacterium. animalis subsp.Lactis A6 Strain
Study NCT06779214 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: resveratrol_H
Description: subject will receive a low-dosage (600mg/d) of resveratrol
Study NCT06779214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo_Bif
Description: subjects will receive placebo (one look-alike sunbstance that contains no prebiotics)
Study NCT06779214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo_resveratrol
Description: subjects will receive placebo (one look-alike sunbstance that contains no resveratrol)
Study NCT06778889 — intervention group
Intervention type: BEHAVIORAL
Intervention: Undergraduate Medical Students
Description: This is an observational study without any intervention. Data will be collected using standardized questionnaires to assess physical activity, mental health, and stress levels in the participants.
Study NCT05787899 — intervention group
Intervention type: OTHER
Intervention: Hypothermia Protocol
Description: Subject's who will be treated with the hypothermia protocol for Hypoxic Ischemic Encephalopathy as standard of care.
Study NCT06296199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR
Description: The participant will be seated comfortably in an armchair. The intervention will last 15 minutes. It will take place once.~This group's intervention will be to watch and listen with VR headphones to a concert by a group of musicians playing music.
Study NCT06296199 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music only
Description: The participant will be seated comfortably in an armchair. The intervention will last 15 minutes. It will take place once.~This group's intervention will be to listen with conventional headphones to a concert by a group of musicians playing music.
Study NCT04450706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Precision Medicine
Description: The tissue from the participant sample will be used for genome sequencing and organoid establishment for drug screening. Both solid tumor genome analysis (commercial and Welm genome) must be performed on tissue from the same biopsy. After the biopsy, the patient will begin uninformed therapy (standard of care or investigational in the context of a separate existing active clinical trial), as selected and directed by the treating physician. Once the results from the genome sequencing and drug screening are available, they will be returned to the treating physician. Upon progression on the uninformed line of therapy, the patient will begin a new therapy as directed by the treating physician. If the patient begins a therapy recommended by the precision oncology results then the next line of therapy will be deemed informed. While receiving the therapy, response assessments will be conducted until documented radiographic or clinical progression.
Study NCT04450706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physican Decision Making
Description: The results from the drug screening and mutation testing will be summarized and returned to the treating physician before the assignment of on study, second-line therapy. Before and after returning results, the treating physician will be administered a survey to assess the potential effect that the precision medicine results have on the selection of the following line of therapy. If a patient begins a therapy that was recommended by the precision medicine results, the therapy will be defined as the informed line of therapy.
Study NCT06090539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986458
Description: Specified dose on specified days.
Study NCT05747937 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Description: A punch skin biopsy of 3mm will be used to analyze cutaneous innervation
Study NCT05747937 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Skin biopsy
Description: A punch skin biopsy of 3mm will be used to analyze cutaneous innervation
Study NCT05747937 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiovascular Reflexes testing
Description: Cardiovascular reflex tests including deep breathing, head-up Tilt, standing, isometric exercises, mental arithmetic and Valsalva maneuver.
Study NCT05747937 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cardiovascular Reflexes testing
Description: Cardiovascular reflex tests including deep breathing, head-up Tilt, standing, isometric exercises, mental arithmetic and Valsalva maneuver.
Study NCT05747937 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Administration of clinical scales evaluating autonomic symptoms, pain small fiber neuropathy symptoms
Description: We'll characterize patients' symptoms through the administration of clinical scales such as: SCOPA-AUT autonomic symptoms scale; Brief Pain Inventory questionnaire
Study NCT05747937 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Administration of clinical scales evaluating autonomic symptoms, pain small fiber neuropathy symptoms
Description: We'll characterize patients' symptoms through the administration of clinical scales such as: SCOPA-AUT autonomic symptoms scale; Brief Pain Inventory questionnaire
Study NCT05747937 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dinamic Sweat Test
Description: Test for the functional assessment of postganglionic sudomotor pathway
Study NCT05747937 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Dinamic Sweat Test
Description: Test for the functional assessment of postganglionic sudomotor pathway
Study NCT06276543 — intervention group
Intervention type: DEVICE
Intervention: antibiotic-impregnated catheter
Description: Hydrocephalus patient implant with antibiotic-impregnated catheter to shunt their cerebrospinal fluid.
Study NCT06077591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-Derived Tumor Organoids
Description: Intervention in this study is to perform tissue sampling to patient's tumor which are then subjected to DNA extraction for whole exome sequencing, organoid culture, and drug screen. An MDT board will review the drug screen results and excluded drug choice of poor response. Then the referring oncologist has the final discretion on the choice of chemo- or targeted agent as usual.
Study NCT06230224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odronextamab
Description: Administered by intravenous (IV) infusion
Study NCT06230224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide
Description: Administered by IV infusion, as part of the ICE ± R salvage therapy
Study NCT06230224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered by IV infusion, as part of the ICE ± R salvage therapy
Study NCT06230224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Administered by IV infusion, as part of the ICE ± R salvage therapy
Study NCT06090539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Specified dose on specified days.
Study NCT06482229 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: application for postoperative analgesia
Description: three different methods will be applied to reduce patients' postoperative pain
Study NCT06230224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Administered by IV infusion, as part of the ICE ± R, or DHAP ± R, or GDP ± R salvage therapy.
Study NCT06230224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Administered by IV, or orally (PO) as part of the DHAP ± R, or GDP ± R salvage therapy.
Study NCT06230224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administered by IV infusion, as part of the DHAP ± R or GDP +/-R salvage therapy.
Study NCT06230224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Administered by IV infusion, as part of the DHAP ± R salvage therapy.
Study NCT06230224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Administered by IV infusion, as part of the GDP ± R salvage therapy.
Study NCT06534983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autogene Cevumeran
Description: Autogene cevumeran will be administered as an IV infusion per the schedule in the specified arm.
Study NCT06534983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered as an IV infusion per the schedule in the specified arm.
Study NCT06778694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor control exercises
Description: Bridging Dead bug Plank Pelvic tilts Squatting and lunges
Study NCT06778694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isolated strengthening lumbar exercises
Description: Child pose Mckenzie Lat pull down Russian twist
Study NCT06534983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab will be administered as an IV infusion per the schedule in the specified arm.
Study NCT06534983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Saline solution for intravenous infusion
Study NCT06548542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous Injection
Study NCT06548542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutikizumab
Description: Subcutaneous Injection
Study NCT06548542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-382
Description: Intravenous Infusion
Study NCT06548542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Intravenous Infusion
Study NCT06548542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-382
Description: Subcutaneous Injection
Study NCT04750252 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: StroMel
Description: Autologous MSC
Study NCT04524000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: \[Part 1\] Alpelisib administered at 200 mg (DL 1), 250 mg (DL 2) or 300mg (DL 3) orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle.~If DL 1 is tolerated, the alpelisib doses of 250 mg will be investigated. If DL 2 is tolerated, the alpelisib doses of 300 mg will be investigated.~\[Part 2\] In the Part 2, participants will be enrolled into Cohort 2 (CDK4/6 inhibitor naive) and Cohort 3 (CDK4/6 inhibitor pre-treated) in parallel and alpelisib will be administered at the recommended dose identified in Part 1.
Study NCT04524000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant is administered at a dose of 500 mg intramuscular on Cycle 1 Day 1, Day 15, and Day 1 of every cycle thereafter (where a cycle is 28 days).
Study NCT05673785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Brentuximab vedotin IV infusion
Study NCT05673785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide IV infusion
Study NCT05673785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin IV infusion
Study NCT05673785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone tablets
Study NCT04681638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pathogen-Reduced Plasma
Description: The treatment group will receive an additional infusion of Pathogen-Reduced Plasma based on the formula, hourly rate, mL/hr = (1 mL\*kg\*TBSA)/24 hr. This infusion will not be titrated. It will be discontinued at the end of the 24th postburn hour.
Study NCT04681638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crystalloid Solutions
Description: The control group will receive an additional infusion of LR based on the formula: hourly rate, mL/hr = (1mL\*kg\*TBSA)/24 hr. this infusion will not be titrated. It will be discontinued at the end of the 24th postburn hour.
Study NCT04927637 — intervention group
Intervention type: PROCEDURE
Intervention: imaging 24 hours following intravenous administration of ICG
Description: Patients will be administered a single, FDA approved, ICG, 2.5-5mg/kg dose 24 hours prior to surgery. ICG fluorescence images will be acquired By a FDA approved surgical imaging device prior to surgical debridement. The wound will be irrigated as per standard procedure and another ICG fluorescence image will be acquired. The need for repeat debridement or tissue cultures will be left up to the treating surgeon.
Study NCT05687539 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mastiha water
Description: 10ml of mastiha water before every meal for one month
Study NCT05687539 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mastiha capsules
Description: 2x350mg mastiha capsules before every meal for one month
Study NCT06565156 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BR-AM
Description: BR-AM is a single-layer amniotic membrane allograft. BR-AM is manufactured by BioStem Technologies, Inc. and is processed by the bioREtain method which, briefly, includes initial disinfection, processing with isotonic solutions, dehydration at 37-40°C and electron beam sterilization.
Study NCT06565156 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard of care is defined as:~* Debridement,~* Wound cleansing with a neutral, non-irritating and non-toxic solution,~* Non-adherent wound contact layer, a foam pad, alginate or hydrofiber dressing for moderately draining wounds, a secondary retention bandage, and~* An off-loading device.
Study NCT06045078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elequil Lavender-peppermint Aromatabs
Description: 100% pure essential oils Lavender-peppermint aromatabs purchased through Beekley Medical
Study NCT06045078 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Elequil Almond-Oil Aromatabs
Description: 100% pure essential oils Almond-oil aromatabs purchased through Beekley Medical
Study NCT05321420 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT05321420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pirfenidone
Description: pirfenidone 801 mg TID
Study NCT05321420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deupirfenidone
Description: Deupirfenidone
Study NCT06312813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipramine
Description: 4% imipramine